

REVIEW

How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice

Jessica L. Fairley^{1,2}, Mandana Nikpour,^{2,3} Heather G. Mack,^{4,5} Maria Brosnan,⁶ Amanda M. Saracino,⁷ Marc Pellegrini^{8,9} and Ian P. Wicks^{1,8,9}

¹Department of Rheumatology, Royal Melbourne Hospital, ²Department of Medicine, The University of Melbourne at St Vincent's Hospital (Melbourne), Departments of ³Rheumatology, and ⁴Cardiology, St. Vincent's Hospital Melbourne, ⁴Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, ⁵Department of Ophthalmology, Melbourne Health, ⁷Department of Medicine, Monash University, ⁸Walter and Eliza Hall Institute of Medical Research, and ⁹Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia

Key words

hydroxychloroquine, systemic lupus erythematosus, rheumatoid arthritis, safety, retinopathy, cardiotoxicity, adverse effects.

Correspondence

Ian P. Wicks, Department of Rheumatology, Royal Melbourne Hospital, 300 Grattan Street, Melbourne, Vic. 3050, Australia.
Email: ian.wicks@mh.org.au;
wicks@wehi.edu.au

Received 25 June 2022; accepted 10 August 2022.

Abstract

Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long-term safety profile than CQ and is therefore more commonly used. HCQ has a key role in the treatment of connective tissue diseases including systemic lupus erythematosus (SLE), where it provides beneficial immunomodulation without clinically significant immunosuppression. HCQ can also assist in managing inflammatory arthritis, including rheumatoid arthritis (RA). Debate around toxicity of HCQ in COVID-19 has challenged those who regularly prescribe HCQ to discuss its potential toxicities. Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice.

Introduction

Hydroxychloroquine (HCQ) plays an important role in the treatment of connective tissue diseases (CTDs), particularly systemic lupus erythematosus (SLE),^{1–3} and in rheumatoid arthritis (RA).⁴ HCQ is a derivative of chloroquine (CQ); both were used initially as antimalarial agents as they interfere with the parasite's ability to degrade and detoxify host haemoglobin, and thus parasite replication.⁵ HCQ has a better side effect profile and so is more widely prescribed than CQ. Most patients with SLE take HCQ at some stage, typically for around 6–7 years.⁶ In SLE, HCQ confers well-documented clinical benefits including increased long-term survival, reduced cumulative steroid doses, protection against accrual of organ damage, reduction in thrombosis and pregnancy complications,^{2,3,7} as well as less risk of developing polyautoimmunity.⁸ HCQ may also improve cardiovascular risk profile – an important

consideration in RA and SLE which are both associated with elevated cardiovascular risk.

The sometimes heated public debate around HCQ's toxicity in the context of potential treatment for coronavirus disease 2019 (COVID-19) provides an opportune moment to reflect on conventional views about its safety and tolerability. Accordingly, we summarise the evidence and provide clinical practice suggestions based on the experience of relevant specialty practitioners (Table 1).

Mechanism of action

Both HCQ and CQ have a long *in vivo* half-life (around 50 days),⁹ reaching steady-state levels after 3 to 6 months.¹⁰ Surprisingly, the mechanism of action of antimalarials in autoimmune disease is still incompletely understood,⁹ but involves effects on both innate and adaptive immunity. HCQ can interfere with intracellular signalling downstream of toll-like receptors, including cytokine production and modulation of co-stimulatory molecule expression.⁹ HCQ has been shown to inhibit the production of multiple cytokines including

Conflict of interest: IW, MB, MP and MN are investigators on the COVID-SHEILD trial of hydroxychloroquine for prevention of COVID-19 in health care workers (Clinical Trial Registration number CT-2020-CTN-01158-1).

Table 1 Summary of frequency of reported adverse events with HCQ

Toxicity	Estimated frequency	Significance
GI disturbance: nausea, vomiting, diarrhoea or loose stool	7–37%	Inform patients. Usually does not require cessation and improves with time
Cutaneous hyperpigmentation	10–25%	Inform patient. Usually improves with discontinuation; depends on patient preference
Myopathy	1.3–12.6%	Infrequently requires cessation
Retinopathy	Clinically significant disease uncommon 0.29–7.5% after 5 years Increasing risk with longer duration of therapy Transient diplopia may also occur on initiation	Usually requires cessation Consult with ophthalmologist, ideally retinal specialist Rare, consult with ophthalmologist
Conduction defects including QT prolongation and torsades de pontes	Rare; case report data	Consider QT monitoring in patients with known LQT or other risk factors (renal impairment, co-prescription of other QT-prolonging medications); consider baseline ECG for reassurance
Cardiomyopathy	Rare; case report data	Case-by-case
Neuropsychiatric symptoms	Rare; case report data	Case-by-case
Hypoglycaemia	Rare; case report data	Consider informing patients at risk of hypoglycaemia (e.g. insulin-dependent diabetes)
Serious cutaneous eruptions	Rare; case report data	Case-by-case
Oxidative haemolysis	Rare; no episodes in recent review of G6PD-deficient patients	N/A
Cytopenias	Rare; not with current dosing regimens	N/A
LFT derangement	Rare; case report data	Case-by-case

G6PD, glucose-6-phosphate dehydrogenase; HCQ, hydroxychloroquine; LFT, liver function; LQT, long QT interval; N/A, not applicable.

interleukin (IL)-1, IL-6, and IL-17, interferon alpha and gamma, and tumour necrosis factor alpha.^{4,11,12} HCQ and CQ are weak bases and therefore raise intracellular pH, which can inhibit the formation of peptide-major histocompatibility complex protein complexes in cytoplasmic compartments, thus reducing stimulation of T cells by antigen-presenting cells.¹³

Ocular toxicity

HCQ can cause retinal damage. The classical pattern of advanced HCQ retinal toxicity is irreversible ‘bull’s eye’ (central) maculopathy. The estimated prevalence of retinal toxicity varies significantly depending on diagnostic criteria, from 0.29¹⁴ to 7.5% after 5 years of therapy¹⁵ (Table S1). The most important risk factors are daily HCQ dose and duration of therapy (especially longer than 5 years).^{14,15} HCQ is significantly renally excreted^{16,17} and retinopathy is more frequent in those with impaired renal function.¹⁵ HCQ blood levels may also be higher in those with renal impairment.¹⁸ Tamoxifen therapy has also been associated with increased risk¹⁵; while tamoxifen can itself cause retinopathy, the reason for its potential synergism with HCQ is unknown. Underlying retinal or macular

disease may confer increased risk,¹⁹ or preclude adequate monitoring because of pre-existing retinal abnormalities.²⁰ Cumulative total doses of 800 g or higher confer increased risk,¹⁴ though less accurate than an assessment based on weight-based daily dose and duration of use.¹⁹ Guidelines aimed at preventing retinal toxicity recommend using less than 5 milligrams of HCQ per kilogram (mg/kg) of actual body weight per day²⁰ or less than 6.5 mg/kg/day of ideal body weight (typically, actual body weight is 25–30% higher than ideal body weight).¹⁵ Actual body weight dosing at 5 mg/kg/day has been shown to reduce excess HCQ dosing, particularly in obese patients, in comparison to dosing based on ideal body weight at 6.5 mg/kg/day.²¹ Age does not appear to significantly increase the risk of retinopathy independent of treatment duration.^{14,15} Monitoring HCQ blood levels may help predict the risk of retinopathy²² but is not routinely available.

The mechanism of retinal toxicity may have a genetic component²³ or reflect HCQ-induced alterations in photoreceptor metabolism.^{14,19} Nonvisually significant corneal deposition can also occur.²⁴ In early retinal toxicity, patients can develop paracentral scotomata.^{14,19} However, subtle early changes are often asymptomatic and only revealed by visual field testing.¹⁹ Location of initial

retinal damage may vary between racial groups²⁵ – parafoveal distribution is more common in Caucasian patients, compared with a peripheral extramacular distribution (near the arcades) in Asian patients.²⁵ African American and Hispanic patients can develop a mixed pattern.²⁵

Physicians who prescribe HCQ long term should refer the patient for ocular monitoring.²⁰ While the American Academy of Ophthalmology (AAO; USA) recommends a baseline eye examination within 1 year of commencing therapy,¹⁹ this is not recommended in the most recent Royal College of Ophthalmologists (RCO; UK) guidelines.²⁰ The RCO cites two reasons for this change: first, only 4% of patients discontinue HCQ because of abnormal baseline eye testing, and second, many patients do not continue HCQ for 5 years and thus never reach a higher risk threshold for toxicity.²⁰ In contrast, the AAO recommends a baseline ophthalmologic examination within 1 year, including visual acuity, corneal/retinal examination with a dilated pupil and (optionally) colour vision testing (to detect preexisting colour-blindness).¹⁹ The AAO does not recommend baseline visual field testing or spectral-domain optical coherence tomography (SD-OCT).¹⁹

Patients taking <5 mg HCQ/kg and without other risk factors (tamoxifen therapy, renal impairment or CQ use) are considered ‘low risk’ and age-appropriate ophthalmologic examinations are sufficient during the first 5 years of therapy, but patients with risk factors should be screened annually from commencement.^{19,20} After 5 years of therapy with HCQ, all patients should be screened annually.^{19,20} Screening aims to detect potentially reversible HCQ toxicity early, before any visual acuity is lost.¹⁹ Automated visual field testing is a subjective, functional test that is widely available and recommended for all patients, although its accuracy depends on patient reliability. SD-OCT is also routinely recommended by both the AAO and RCO^{19,20}; it provides detailed imaging of the retina and can demonstrate thinning of photoreceptor layers. Widefield fundus autofluorescence (FAF) may detect early retinal pigment epithelial cell damage, prior to abnormality on SD-OCT. Multifocal electroretinography may be useful in those with persistent visual field defects but no structural defects on SD-OCT or FAF.²⁰

Cardiac toxicity and QT prolongation

Clinically significant QT prolongation and cardiotoxicity with antimalarials are rarely seen in rheumatology practice.²⁶ Case reports describe conduction disorders (prolonged QT interval, AV block, intraventricular conduction delays), left ventricular hypertrophy (LVH)

and heart failure,²⁶ as well as QT interval prolongation and subsequent torsade de pointes (TdP).^{27,28} These findings have not been reproduced in prospective studies.²⁹

There has been an explosion of concern regarding the risk of QT prolongation with the combination of high-dose HCQ (600–800 mg/day) and azithromycin for COVID-19.³⁰ Population-based studies suggest that a prolonged QT interval may occur in up to 8.7% of individuals over time in the setting of acute illness, electrolyte disturbance or QT-prolonging medications.³¹ The frequency of clinically significant complications from QT prolongation in these clinical settings is unclear. In COVID-19 patients taking high-dose HCQ and azithromycin, very low/no incidence of ventricular arrhythmias or TdP has been described.³⁰ Prolonged QT can also occur with many commonly used medications, such as antiarrhythmics, some antimicrobials (e.g. macrolides including azithromycin, fluoroquinolones, antifungals and some antivirals), antidepressants, methadone, tamoxifen and antipsychotic medications.³² Other risk factors include electrolyte abnormalities, renal failure, heart failure or ischemic heart disease. We could not find evidence that baseline or interval QT monitoring is recommended routinely when prescribing these medications, although caution is emphasised with known long QT syndrome. In a study of 681 patients with RA and SLE without clinical cardiovascular disease, HCQ did not predict prolonged QTc.²⁹ Nine of 681 patients taking HCQ had a QTc greater than 500 ms, with no arrhythmias or deaths.²⁹ A longer QTc in patients taking antipsychotic agents and HCQ was seen compared with HCQ alone (441 ms vs 432 ms), but no significant associations were seen with other QT-prolonging medications.²⁹

LVH and cardiomyopathy can rarely occur with HCQ, possibly attributable to impaired lysosomal enzyme function and accumulation of pathologic metabolites (such as phospholipid and glycogen), disturbing membrane stability and signal transduction in cardiac myocytes.^{33,34} Decreased myocardial contractility may occur with higher doses or longer duration of therapy (especially >10 years)³³; other risk factors may include older age, female sex, renal failure and preexisting cardiac disease.³⁴ Both HCQ-induced cardiac failure and arrhythmias are considered reversible with drug cessation.¹⁰ Retrospective data suggest HCQ use in SLE is in fact protective against incident atrial fibrillation despite the significant prevalence of AF risk factors in these HCQ users.³⁵

In summary, recent prospective data and longstanding clinical experience with HCQ in rheumatology would not suggest that prolonged QT is a clinically significant problem. Firm evidence is lacking, and no guidelines

from specialty societies exist. A 12-lead ECG to exclude baseline QT prolongation can be considered in people with other risk factors (e.g. renal failure, significant history of cardiovascular disease or QT-prolonging medications).

Gastrointestinal side effects

Gastrointestinal (GI) disturbance is relatively common with commencing HCQ (7–37%),^{6,36} especially nausea/vomiting and diarrhoea/loose stool. The prevalence of these symptoms increases with higher doses but often reduces over time.³⁶ Although occasionally severe enough to warrant discontinuation, at doses of 400 mg/day or less this is uncommon.³⁶ To ameliorate GI upset, HCQ can be taken with food, the dose can be divided, or liquid formulation may be trialled.

Deranged liver function tests may infrequently occur with HCQ, especially in those patients with underlying liver disease; however, overt drug-induced hepatitis is rare.³⁷

Cutaneous reactions

Mucocutaneous blue-grey hyperpigmentation can occur in up to 25% of patients taking long-term antimalarials.³⁸ Hyperpigmentation typically occurs on the face, distal extremities, oral mucosa, nails or within scars.^{38,39} The pathogenesis of mucocutaneous hyperpigmentation is poorly understood, but CQ has affinity for melanin.³⁸ Mucocutaneous hyperpigmentation may be a marker of ocular toxicity.³⁹ Skin pigmentation can cause cosmetic concern and patients taking long-term HCQ should be informed about it. Improvement can sometimes occur without drug discontinuation.³⁹

Pruritic morbilliform drug eruptions can occur, which are typically mild and resolve after cessation.^{40,41} Reintroduction of low-dose HCQ or alternative antimalarials using desensitisation protocols may be successful.⁴¹ Acute cutaneous reactions tend to occur within the first 4 weeks of commencing treatment,⁴² and may include acute generalised exanthematous pustulosis, drug eruption with eosinophilia and systemic symptoms syndrome, erythema multiforme, Stevens–Johnson syndrome or toxic epidermal necrolysis. Some rheumatological diseases may confer a higher risk for acute cutaneous reactions, such as dermatomyositis.⁴¹ Severe acute cutaneous reactions are rare and can recur with rechallenge, so in these cases antimalarials should be avoided.⁴²

Photosensitivity with HCQ is reported but is very uncommon.⁴³ Because of its impact on keratinisation, HCQ may induce psoriasiform hyperplasia.⁴¹ Literature

supporting the risk of HCQ-induced exacerbation of psoriasis is mixed; observational data suggest up to 31% of patients with psoriasis experience a flare caused by HCQ, but a recent systemic review highlighted a lack of high-quality evidence to support a causal relationship.⁴¹

Neuromuscular toxicities

Estimates of the prevalence of neuromuscular disease with HCQ vary widely, from 1.3%⁶ to 12.6%.⁴⁴ Risk factors may include Caucasian background, renal dysfunction and coadministration of other myotoxic drugs.⁴⁵ Myotoxicity is characterised by weakness and abnormal muscle enzymes (e.g. creatinine kinase, lactate dehydrogenase or aldolase). There are similar histological features between HCQ-induced cardiomyopathy and skeletal myopathy.³⁴ Mechanistically, myopathy may relate to accumulation of intracellular debris in autophagic vacuoles⁴⁴ and lysosomal damage.⁴⁶ HCQ-induced muscle weakness is not always present even with abnormal muscle enzymes,⁴⁴ but, rarely, it may be severe, including respiratory involvement.⁴⁶ Myopathy is considered reversible on cessation of HCQ.⁴⁴

Neuropsychiatric symptoms have been attributed to HCQ although are rarely encountered in rheumatology practice. Case reports include psychomotor agitation/aggression,⁴⁷ psychosis,⁴⁸ mood disorders and suicidality.⁴⁹ Possible predisposing factors include low body weight, family history, concomitant prednisolone therapy, alcohol and drug interactions including CYP3A4 inhibitors (which can increase HCQ levels) and p-glycoprotein inhibitors (which may increase blood–brain barrier permeability to HCQ).⁵⁰

Metabolic and haematological considerations

HCQ can reduce haemoglobin A1c and blood glucose in patients with RA⁵¹ and thus reduce the risk of type 2 diabetes mellitus (DM). This effect may be mediated by increased pancreatic insulin production and secretion, or decreased insulin clearance.⁵¹ The anti-inflammatory effects of antimalarials may also contribute to lowering of glucose and lipid levels, and thus improve cardiovascular risk profiles in at-risk populations.⁵² Clinically significant hypoglycaemia may rarely occur with⁵³ or without underlying DM.⁵⁴ HCQ may reduce insulin requirements in patients with insulin-dependent DM by up to 30%,⁵³ with concomitant reduction in haemoglobin A1c levels (1–3%).⁵⁵ Those with difficult to control diabetes should be informed of this when commencing HCQ.

The largest review to date of HCQ in rheumatology patients found no episodes of haemolysis in G6PD-deficient patients.⁵⁶ Leukopenia and aplastic anaemia are extremely rare with modern dosing regimens.⁵⁷

The bigger picture

Outside of retinal toxicity, treatment-limiting toxicity with HCQ is rare in clinical practice. In SLE, HCQ remains the only agent with a demonstrable mortality benefit.¹ HCQ is not only safe but encouraged in pregnancy and breastfeeding, improving pregnancy outcomes in SLE² and the risk of thrombosis and pregnancy loss in the antiphospholipid syndrome.³ HCQ reduces the risk of neonatal lupus and congenital heart block by more than 50% in anti-SSA/Ro positive women with a history of a previously affected pregnancy.⁵⁸ Current dosing recommendations of 5 mg/kg/day were developed to mitigate the risk of retinal toxicity rather than to maximise efficacy.⁵⁹ The European League Against Rheumatism recommends dose-reducing patients with long-standing stable disease⁵⁹ with some data suggesting no increased risk of flare when reducing from 6.5 to 5 mg/kg/day.⁶⁰ However, recent data raise the question of whether body weight dosing is the ideal method of HCQ dosing. HCQ blood levels are not widely available, but may assist in stratifying the risk of retinal toxicity as well as assessing adherence²² and predicting flares, with data demonstrating a higher risk of disease flare in those with lower HCQ blood levels.^{61,62} Furthermore, recent data suggest lower efficacy and a significantly higher risk of thrombotic events in SLE patients with lower HCQ blood levels.⁶³

References

- Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM *et al.* Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). *Ann Rheum Dis* 2007; **66**: 1168–72.
- Sciascia S, Hunt BJ, Talavera-Garcia E, Liso G, Khamashta MA, Cuadrado MJ. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. *Am J Obstet Gynecol* 2016; **214**: 273e1–8.
- Mekinian A, Lazzaroni MG, Kuzenko A, Alijotas-Reig J, Ruffatti A, Levy P *et al.* The efficacy of hydroxychloroquine for obstetrical outcome in antiphospholipid syndrome: data from a European multicenter retrospective study. *Autoimmun Rev* 2015; **14**: 498–502.
- Silva JC, Mariz HA, Rocha LF Jr, Oliveira PS, Dantas AT, Duarte AL *et al.* Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. *Clinics* 2013; **68**: 766–71.
- Schaer CA, Laczko E, Schoedon G, Schaer DJ, Vallelian F. Chloroquine interference with hemoglobin endocytic trafficking suppresses adaptive heme and iron homeostasis in macrophages: the paradox of an antimalarial agent. *Oxid Med Cell Longev* 2013; **2013**: 870472.
- Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM. Discontinuation of antimalarial drugs in systemic lupus erythematosus. *J Rheumatol* 1999; **26**: 808–15.
- Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). *Expert Opin Drug Saf* 2017; **16**: 411–9.
- Mena-Vazquez N, Fernandez-Nebro A, Pego-Reigosa JM, Galindo M, Melissa-Anzola A, Uriarte-Isacelay E *et al.* Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER registry. *Rheumatology* 2019; **59**: 2043–51.
- Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol* 2020; **16**: 155–66.
- Nord JE, Shah PK, Rinaldi RZ, Weisman MH. Hydroxychloroquine cardiotoxicity in systemic lupus

Conclusion

HCQ continues to play a pivotal role in managing rheumatic diseases. Despite widespread media debate in the context of COVID, it is an effective, inexpensive and comparatively safe disease-modifying therapy in SLE, providing beneficial immunomodulation without clinically significant immunosuppression. As an adjunctive to disease-modifying agents in RA, HCQ has potential added benefits for improving metabolic syndrome and cardiovascular risk profile. Retinal toxicity is a recognised side effect, with continually evolving guidelines for monitoring this risk, but other toxicities appear to be rare. Systematic assessment of the potential nonretinal toxicities of HCQ as prescribed in typical clinical practice would be helpful, particularly of the significance of QT prolongation. However, while endorsing the need for continual refinements to optimise the safe prescribing of HCQ, we believe it is also important to allay anxieties about what most clinicians would regard as a tried and trusted drug.

Acknowledgements

IW holds a Practitioner Fellowship and a Program Grant from NHMRC (1154325 and 1113577), MN holds an NHMRC Investigator Grant (GNT1176538) and MP holds an NHMRC Investigator Grant (GNT1175011). JF holds an NHMRC Postgraduate Scholarship (GNT2013842) and an Australian Government Research Training Program Scholarship. Open access publishing facilitated by The University of Melbourne, as part of the Wiley - The University of Melbourne agreement via the Council of Australian University Librarians.

- erythematosus: a report of 2 cases and review of the literature. *Semin Arthritis Rheum* 2004; **33**: 336–51.
- 11 Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. *J Rheumatol* 1993; **20**: 803–8.
 - 12 van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. *J Rheumatol* 1997; **24**: 55–60.
 - 13 Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on toll-like receptors? *Arthritis Rheum* 2006; **54**: 3068–70.
 - 14 Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. *Arthritis Care Res* 2010; **62**: 775–84.
 - 15 Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. *JAMA Ophthalmol* 2014; **132**: 1453–60.
 - 16 Browning D. Hydroxychloroquine and Chloroquine Retinopathy; 2014.
 - 17 Nicol MR, Joshi A, Rizk ML, Sabato PE, Savic RM, Wesche D et al. Pharmacokinetics and pharmacological properties of chloroquine and hydroxychloroquine in the context of COVID-19 infection. *Clin Pharmacol Ther* 2020; **108**: 1135–49.
 - 18 Lee JY, Luc S, Greenblatt DJ, Kalish R, McAlindon TE. Factors associated with blood hydroxychloroquine level in lupus patients: renal function could be important. *Lupus* 2013; **22**: 541–2.
 - 19 Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on screening for chloroquine and Hydroxychloroquine retinopathy (2016 revision). *Ophthalmology* 2016; **123**: 1386–94.
 - 20 The Royal College of Ophthalmologists. Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Monitoring; 2020.
 - 21 Jorge AM, Melles RB, Zhang Y, Lu N, Rai SK, Young LH et al. Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. *Arthritis Res Ther* 2018; **20**: 133.
 - 22 Petri M, Elkhalfi M, Li J, Magder LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. *Arthritis Rheumatol* 2020; **72**: 448–53.
 - 23 Grassmann F, Bergholz R, Mandl J, Jagle H, Ruether K, Weber BH. Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy). *BMC Ophthalmol* 2015; **15**: 18.
 - 24 Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. *Ann Rheum Dis* 2010; **69**: 20–8.
 - 25 Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. *Ophthalmology* 2015; **122**: 110–6.
 - 26 Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. *Drug Saf* 2018; **41**: 919–31.
 - 27 Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. *J Clin Rheumatol* 2013; **19**: 286–8.
 - 28 O’Laughlin JP, Mehta PH, Wong BC. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. *Case Rep Cardiol* 2016; **2016**: 4626279.
 - 29 Park E, Giles JT, Perez-Recio T, Pina P, Depender C, Bathon J et al. Hydroxychloroquine use was not associated with QTc length in a large cohort of SLE and RA patients (abstract). *Arthritis Rheumatol* 2020; **72** (suppl 10). <https://acrabstracts.org/abstract/hy>
 - 30 Saleh M, Gabriels J, Chang D, Soo Kim B, Mansoor A, Mahmood E et al. Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. *Circ Arrhythm Electrophysiol* 2020; **13**: e008662.
 - 31 Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. *Arch Intern Med* 2004; **164**: 943–8.
 - 32 Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. *Heart* 2003; **89**: 1363–72.
 - 33 Page RL 2nd, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. *Circulation* 2016; **134**: e32–69.
 - 34 Tonnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy – a review of the literature. *Immunopharmacol Immunotoxicol* 2013; **35**: 434–42.
 - 35 Gupta A, Shields KJ, Manzi S, Wasko MC, Sharma TS. Association of hydroxychloroquine use with decreased incident atrial fibrillation in systemic lupus erythematosus. *Arthritis Care Res* 2021; **73**: 828–32.
 - 36 Furst DE, Lindsley H, Baethge B, Botstein GR, Caldwell J, Dietz F et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. *Arthritis Rheum* 1999; **42**: 357–65.
 - 37 Giner Galvan V, Oltra MR, Rueda D, Esteban MJ, Redon J. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. *Clin Rheumatol* 2007; **26**: 971–2.
 - 38 Hendrix JD Jr, Greer KE. Cutaneous hyperpigmentation caused by systemic drugs. *Int J Dermatol* 1992; **31**: 458–66.
 - 39 Millard TP, Kirk A, Ratnavel R. Cutaneous hyperpigmentation during therapy with hydroxychloroquine. *Clin Exp Dermatol* 2004; **29**: 92–3.
 - 40 Chew CY, Mar A, Nikpour M, Saracino AM. Hydroxychloroquine in dermatology: new perspectives on an old drug. *Australas J Dermatol* 2020; **61**: e150–7.
 - 41 Herman SM, Shin MH, Holbrook A, Rosenthal D. The role of antimalarials in the exacerbation of psoriasis: a systematic review. *Am J Clin Dermatol* 2006; **7**: 249–57.
 - 42 Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with

- dermatomyositis than in patients with cutaneous lupus erythematosus. *Arch Dermatol* 2002; **138**: 1231–3 discussion 3.
- 43 Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. *J Rheumatol* 1991; **18**: 188–94.
- 44 Casado E, Gratacos J, Tolosa C, Martinez JM, Ojanguren I, Ariza A *et al*. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. *Ann Rheum Dis* 2006; **65**: 385–90.
- 45 Gilman AL, Chan KW, Mogul A, Morris C, Goldman FD, Boyer M *et al*. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. *Biol Blood Marrow Transplant* 2000; **6**: 327–34.
- 46 Kwon JB, Kleiner A, Ishida K, Godown J, Cialfoni E, Looney RJ Jr. Hydroxychloroquine-induced myopathy. *J Clin Rheumatol* 2010; **16**: 28–31.
- 47 Manzo C, Gareri P, Castagna A. Psychomotor agitation following treatment with Hydroxychloroquine. *Drug Saf Case Rep* 2017; **4**: 6.
- 48 Ward WQ, Walter-Ryan WG, Shehi GM. Toxic psychosis: a complication of antimalarial therapy. *J Am Acad Dermatol* 1985; **12**: 863–5.
- 49 de Oliveira P, Ribeiro N, de Mello R, Schier A, Ornelas AC, Pinho de Oliveira CM *et al*. Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. *Compr Psychiatry* 2013; **54**: 1185–9.
- 50 Mascolo A, Berrino PM, Gareri P, Castagna A, Capuano A, Manzo C *et al*. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. *Inflammopharmacology* 2018; **26**: 1141–9.
- 51 Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF *et al*. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. *JAMA* 2007; **298**: 187–93.
- 52 Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J *et al*. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. *Ann Rheum Dis* 2018; **77**: 98–103.
- 53 Shojania K, Koehler BE, Elliott T. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. *J Rheumatol* 1999; **26**: 195–6.
- 54 Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. *Rheumatology* 2008; **47**: 378–9.
- 55 Hage MP, Al-Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. *Ther Adv Endocrinol Metab* 2014; **5**: 77–85.
- 56 Mohammad S, Clowse MEB, Eudy AM, Criscione-Schreiber LG. Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-deficient patients. *Arthritis Care Res* 2018; **70**: 481–5.
- 57 Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. *Dermatol Ther* 2007; **20**: 160–74.
- 58 Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA *et al*. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA/Ro-positive mothers. *J Am Coll Cardiol* 2020; **76**: 292–302.
- 59 Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN *et al*. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis* 2019; **78**: 736–45.
- 60 Vazquez-Otero I, Medina-Cintron N, Arroyo-Avila M, Gonzalez-Sepulveda L, Vila LM. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus. *Lupus Sci Med* 2020; **7**: e000395.
- 61 Pedrosa TN, Pasoto SG, Aikawa NE, Yuki EF, Borba EF, Filho JCF *et al*. Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. *Lupus* 2020; **29**: 560–8.
- 62 Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P *et al*. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. *Arthritis Rheum* 2006; **54**: 3284–90.
- 63 Petri M, Konig MF, Li J, Goldman DW. Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus. *Arthritis Rheumatol* 2021; **73**: 997–1004.

Supporting Information

Additional supporting information may be found in the online version of this article at the publisher's web-site:

Table S1 Summary of the frequency and variation of reported ocular toxicity of HCQ